FDA hands down a partial hold for PhI/II trial of Blueprint’s CDK2 inhibitor
The FDA is giving one of Blueprint Medicines’ trials a partial clinical hold.
On Friday, the Massachusetts-based biotech said the FDA informed Blueprint two days ago that it is placing a partial hold on a Phase I/II study, also known as the VELA trial, looking at BLU-222 in advanced solid tumors. The partial hold was due to adverse events being observed in a “limited number” of patients, Blueprint said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.